BioXcel Therapeutics (BTAI) Reports Positive Topline Results

BioXcel Therapeutics (BTAI) Reports Positive Topline Results From TRANQUILITY II Phase 3 Trial of BXCL501

BioXcel Therapeutics (BTAI) Reports Positive Topline Results From TRANQUILITY II Phase 3 Trial of BXCL501
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Vimal Mehta , Scott Stachowiakrusso , Corporatebioxcel Therapeuticserik Kopp , George Grossberg , Robert Risinger , Relationsbioxcel Therapeuticsbrennan Doyle , While The Company , Department Of Psychiatry Behavioral Neuroscience At St , Division Of Geriatric Psychiatry , Bioxcel Therapeutics Inc , Securities Exchange , Louis University School Of Medicine , Company Current Report On Form , Nasdaq , Bioxcel Therapeutics , Negative Syndrome Scale Excitatory Component , Director Division , Geriatric Psychiatry , Behavioral Neuroscience , Louis University School , Primary Endpoint , Scorefrom Baseline , Special Interest Reported Within , Chief Medical Officer , Breakthrough Therapy Designation , Xcel Therapeutics , Current Report , Agitation Calmness Evaluation Scale , Clinical Global Impressions , Improvement Scale , Major Depressive , Breakthrough Therapy , Fast Track , Onkosxcel Therapeutics , Looking Statementsthis , Private Securities Litigation Reform Act , Securities Act , Securities Exchange Act , Quarterly Report , Bioxcel Therapeuticserik Kopp , David Schull , Scott Stachowiakrusso Partners ,